Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136941

Published: 2020

Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Blood (2019) 134 (Supplement_1): 4073.

https://doi.org/10.1182/blood-2019-122948

Published: 2019

Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Blood (2019) 134 (Supplement_1): 3046.

https://doi.org/10.1182/blood-2019-125895

Published: 2019

Journal Articles

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Annamaria Brioli, MD, Kirsi Manz, Mathias Hänel, MD, Markus Pfirrmann, PhD, Andreas Christoph Schwarzer, MD, Marie von Lilienfeld-Toal, MD, Gabriele Prange-Krex, Christian Fabisch, PhD, Stefan Knop, Thomas Illmer, MD, Beate Krammer-Steiner, Andreas Hochhaus, MD, Lars-Olof Mügge, MD

Blood (2018) 132 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2018-99-115964

Published: 2018

Journal Articles

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Julia von Tresckow, MD, Paula Cramer, MD, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Thomas Illmer, MD, Holger Klaproth, MD, Sven Estenfelder, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, MD, Michael Hallek

Blood (2016) 128 (22): 640.

https://doi.org/10.1182/blood.V128.22.640.640

Published: 2016

Journal Articles

Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Blood (2015) 126 (23): 599.

https://doi.org/10.1182/blood.V126.23.599.599

Published: 2015

Journal Articles

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, MD, Martin Griesshammer, MD, Thomas Illmer, MD, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, MD, Renato S Tavares, MD, Alessandro M. Vannucchi, MD, Pilar Giraldo, MD PhD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Bayane Tannir, Julian Perez Ronco, MD, Jaggannath Ghosh, Haifa Kathrin Al-Ali, MD

Blood (2014) 124 (21): 3197.

https://doi.org/10.1182/blood.V124.21.3197.3197

Published: 2014

Journal Articles

Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Francesc Bosch, MD PhD, Thomas Illmer, MD, Mehmet Turgut, MD PhD, Agostino Cortelezzi, MD, Susan F. Lasserre, MSc, Anna Truppel-Hartmann, MD, Veronique Leblond, MD PhD, Robin Foà, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 3345.

https://doi.org/10.1182/blood.V124.21.3345.3345

Published: 2014

Journal Articles

Expression of the Nuclear Corepressor Ski Predicts Response to Histone Deacetylase Inhibitor Valproic Acid in Cells of Acute Myeloid Leukemia.

Sabine Teichler, Cornelia A Brendel, MD, Thomas Illmer, MD, Thorsten Stiewe, MD, Lisa-Marie Weiss, Andreas Neubauer, MD

Blood (2012) 120 (21): 2410.

https://doi.org/10.1182/blood.V120.21.2410.2410

Published: 2012

Journal Articles

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

Friedrich Stölzel, MD, David M. Poitz, PhD, Laleh S. Arabanian, Jens Friedrichs, PhD, Denitsa Docheva, PhD, Matthias Schieker, MD, Fernando A. Fierro, PhD, Uwe Platzbecker, MD, Ruth H. Strasser, MD, Martin Bornhäuser, MD, Carsten Werner, PhD, Gerhard Ehninger, Thomas Illmer, MD

Blood (2012) 120 (21): 3459.

https://doi.org/10.1182/blood.V120.21.3459.3459

Published: 2012

Journal Articles

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Friedrich Stöolzel, MD, Thomas Illmer, MD, Claudia Dill, Michael Kramer, Brigitte Mohr, Christian Thiede, MD, Uwe Platzbecker, MD, Johannes Schetelig, MD, Christoph Röllig, MD, Martin Bornhäuser, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2011) 118 (21): 935.

https://doi.org/10.1182/blood.V118.21.935.935

Published: 2011

Journal Articles

Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Results of a Phase I/II Trial.

Martin Bornhaeuser, MD, Thomas Illmer, MD, Platzbecker Uwe, MD, Ordemann Rainer, MD, Schetelig Johannes, MD, Schaich Markus, MD, Kiani Alexander, MD, Schuler Ulrich, MD, Ehninger Gerhard, MD

Blood (2007) 110 (11): 1997.

https://doi.org/10.1182/blood.V110.11.1997.1997

Published: 2007

Journal Articles

Elderly Patients with Acute Myeloid Leukemia Are Not All the Same: Results of the Prospective DSIL AML96 Trial.

Markus Andreas Schaich, MD, Walter E. Aulitzky, MD, Heinrich Bodenstein, MD, Martin Bornhaeuser, MD, Thomas Illmer, MD, Ulrike Schaekel, MD, Norbert Schmitz, MD, Ulrich S. Schuler, MD, Silke Soucek, Christian Thiede, MD, Hannes Wandt, MD, Gerhard Ehninger, MD

Blood (2007) 110 (11): 1840.

https://doi.org/10.1182/blood.V110.11.1840.1840

Published: 2007

Journal Articles

Detection of Herpesvirus and Adenovirus Infections in Patients Undergoing Stem Cell Transplantation: Looking Below the Tip of the Iceberg with the Microarray Technology.

Anette Ditzen, MD, Markus Stichling, Rene Mueller, Anke Rutzka, Kristine Hille, Thomas Illmer, MD, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Enno Jacobs, MD, Ralf Ehricht, Jacques Rohayem, MD

Blood (2007) 110 (11): 4977.

https://doi.org/10.1182/blood.V110.11.4977.4977

Published: 2007

Journal Articles

Insertion and Deletions Mutations of the CEBPA Gene Affecting the bZIP Region Are Strong Predictors for Achieving Complete Remission and Improved Overall Survival in Adult Patients with AML - An Analysis in 1536 Patients Treated in the AML96 Protocol of the DSIL.

Christian Thiede, MD, Franziska Taube, Thomas Illmer, MD, Markus Schaich, MD, Gerhard Ehninger, MD

Blood (2007) 110 (11): 3484.

https://doi.org/10.1182/blood.V110.11.3484.3484

Published: 2007

Journal Articles

Early Treatment Intensification in High Risk (HR)-AML Patients Using Allogeneic Hematopoietic Stem Cell Transplantion in a Randomized Multicenter Setting.

Thomas Illmer, MD, Markus A. Schaich, MD, Christian Thiede, MD, Uwe Platzbecker, MD, Wandt Hannes, MD, Ho D. Anthony, MD, Thiel Eckhard, MD, Schmitz Norbert, MD, Einsele Hermann, MD, Neubauer Andreas, MD, Andresen Reinhard, MD, Aulitzky Walter, MD, Haehnel Matthias, MD, Serve Hubert, MD, Berdel Wolfgang, MD, Bornhaeuser Martin, MD, Ehninger Gerhard, MD

Blood (2007) 110 (11): 3018.

https://doi.org/10.1182/blood.V110.11.3018.3018

Published: 2007

Journal Articles

Inhibition of PDGFRβ by Imatinib Mesylate Suppresses Proliferation and Alters Differentiation of Human Mesenchymal Stem Cells In Vitro.

Fernando Fierro, Thomas Illmer, MD, Duhoui Jing, Philip Le Coutre, MD, Gerhard Ehninger, MD, Sabine Boxberger, Martin Bornhaeuser, MD

Blood (2006) 108 (11): 2563.

https://doi.org/10.1182/blood.V108.11.2563.2563

Published: 2006

Journal Articles

MiRNA Expression Signatures in Acute Myeloid Leukemia Are Predictors for Patient Outcome.

Thomas Illmer, MD, David Kosel, Markus A. Schaich, MD, Christian Thiede, MD, Andreas Neubauer, MD, Carsten Mueller-Tidow, MD, Martin Bornhaeuser, MD, Alex Kiani, MD, Gerhard Ehninger, MD, David Brown, PhD, Dimitriy Ovcharenko, PhD

Blood (2006) 108 (11): 152.

https://doi.org/10.1182/blood.V108.11.152.152

Published: 2006

Journal Articles

DNA-Microarray for Simultaneous Detection of Herpesviruses and Adenovirus in Patients Undergoing Allogeneic Stem Cell Transplantation.

Anette K. Ditzen, MD, Anke Rutzka, Markus Stichling, Rene Mueller, Ralf Ehricht, Thomas Illmer, MD, Martin Bornhaeuser, MD, Enno Jacobs, MD, Jacques Rohayem, MD

Blood (2006) 108 (11): 2937.

https://doi.org/10.1182/blood.V108.11.2937.2937

Published: 2006

Journal Articles

Hematopoietic Progenitor Cells Harbouring BCR-ABL Exhibit Increased Adhesiveness but an Impaired Migration and Homing Potential.

Fernando A. Fierro, Anja Taubenberger, Gerhard Ehninger, MD, Daniel Mueller, PhD, Martin Bornhaeuser, MD, Thomas Illmer, MD

Blood (2006) 108 (11): 4807.

https://doi.org/10.1182/blood.V108.11.4807.4807

Published: 2006

NARROW

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Expression of the Nuclear Corepressor Ski Predicts Response to Histone Deacetylase Inhibitor Valproic Acid in Cells of Acute Myeloid Leukemia.

Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Results of a Phase I/II Trial.

Elderly Patients with Acute Myeloid Leukemia Are Not All the Same: Results of the Prospective DSIL AML96 Trial.

Detection of Herpesvirus and Adenovirus Infections in Patients Undergoing Stem Cell Transplantation: Looking Below the Tip of the Iceberg with the Microarray Technology.

Insertion and Deletions Mutations of the CEBPA Gene Affecting the bZIP Region Are Strong Predictors for Achieving Complete Remission and Improved Overall Survival in Adult Patients with AML - An Analysis in 1536 Patients Treated in the AML96 Protocol of the DSIL.

Early Treatment Intensification in High Risk (HR)-AML Patients Using Allogeneic Hematopoietic Stem Cell Transplantion in a Randomized Multicenter Setting.

Inhibition of PDGFRβ by Imatinib Mesylate Suppresses Proliferation and Alters Differentiation of Human Mesenchymal Stem Cells In Vitro.

MiRNA Expression Signatures in Acute Myeloid Leukemia Are Predictors for Patient Outcome.

DNA-Microarray for Simultaneous Detection of Herpesviruses and Adenovirus in Patients Undergoing Allogeneic Stem Cell Transplantation.

Hematopoietic Progenitor Cells Harbouring BCR-ABL Exhibit Increased Adhesiveness but an Impaired Migration and Homing Potential.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only